RL
Therapeutic Areas
Boston Immune Technologies & Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BITR2101 | Oncology (via TNFR2) | Phase I |
| BITT311 | Autoimmunity / Inflammation (via CD40) | IND Enabling |
| Undisclosed | Autoimmunity / Inflammation (via OX40) | Discovery |
Leadership Team at Boston Immune Technologies & Therapeutics
DB
David Brooks
Chief Medical Officer
EE
Elena Ende
Finance Director
BW
Bruce Weaver
VP of Manufacturing
MR
Mohammad Razvi
Director of Clinical Operations and Development